Sigma proteins : evolution of the concept of sigma receptors /

Saved in:
Bibliographic Details
Imprint:Cham, Switzerland : Springer, [2017]
©2017
Description:1 online resource (viii, 330 pages) : illustrations (chiefly color)
Language:English
Series:Handbook of experimental pharmacology, 1865-0325 ; volume 244
Handbook of experimental pharmacology ; v. 244.
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11384476
Hidden Bibliographic Details
Other authors / contributors:Kim, Felix J., editor.
Pasternak, Gavril W., editor.
ISBN:9783319658537
3319658530
9783319658513
3319658514
Digital file characteristics:text file PDF
Notes:Includes bibliographical references.
Online resource; title from electronic title page (SpringerLink, viewed November 2, 2017).
Summary:"Two sigma receptor subtypes have been proposed, sigma1 and 2. Much of our understanding of this system is based on biochemical and pharmacological characterization of the cloned sigma1 receptor subtype (Sigma1). It has become clear that sigma receptors are not canonical receptors. Sigma1 is highly conserved among mammalian species, however, it does not share significant homology with any other mammalian protein. Although a range of structurally diverse small molecules bind Sigma1 with high affinity, and it has been associated with a broad range of signaling systems, Sigma1 itself has no known signaling or enzymatic activity. The evolution of this field over nearly four decades has more recently led to a fundamental shift in the concept of "sigma receptors" to what may more accurately and generally be called sigma proteins. Largely based on traditional pharmacologic approaches, the Sigma1 protein has been associated with a broad range of signaling systems, including G-protein coupled receptors, NMDA receptors, and ion channels. Sigma proteins have been linked to a range of physiological processes, including intracellular calcium signaling, neuroprotection, learning, memory, and cognition. Emerging genetic, clinical, and mechanism focused molecular pharmacology data demonstrate the involvement of proteins in a range of pathophysiologies and disorders including neurodegenerative disease, pain, addiction, psychomotor stimulant abuse, and cancer. However, an understanding of the physiological role of sigma proteins has remained elusive. Emerging data associate Sigma1 with chaperone-like activities or molecular scaffold functions. This book aims to provide an updated perspective on this rapidly evolving field undergoing changes in fundamental concepts of key importance to the discipline of pharmacology. It focusses on the reported roles of sigma proteins in pathophysiology and on emergent therapeutic initiatives"--Publisher's description.
"Two sigma receptor subtypes have been proposed, sigma1 and 2. Much of our understanding of this system is based on biochemical and pharmacological characterization of the cloned sigma1 receptor subtype (Sigma1). It has become clear that sigma receptors are not canonical receptors. Sigma1 is highly conserved among mammalian species, however, it does not share significant homology with any other mammalian protein. Although a range of structurally diverse small molecules bind Sigma1 with high affinity, and it has been associated with a broad range of signaling systems, Sigma1 itself has no known signaling or enzymatic activity. The evolution of this field over nearly four decades has more recently led to a fundamental shift in the concept of ٢sigma receptors٣ to what may more accurately and generally be called sigma proteins. Largely based on traditional pharmacologic approaches, the Sigma1 protein has been associated with a broad range of signaling systems, including G-protein coupled receptors, NMDA receptors, and ion channels. Sigma proteins have been linked to a range of physiological processes, including intracellular calcium signaling, neuroprotection, learning, memory, and cognition. Emerging genetic, clinical, and mechanism focused molecular pharmacology data demonstrate the involvement of proteins in a range of pathophysiologies and disorders including neurodegenerative disease, pain, addiction, psychomotor stimulant abuse, and cancer. However, an understanding of the physiological role of sigma proteins has remained elusive. Emerging data associate Sigma1 with chaperone-like activities or molecular scaffold functions. This book aims to provide an updated perspective on this rapidly evolving field undergoing changes in fundamental concepts of key importance to the discipline of pharmacology. It focusses on the reported roles of sigma proteins in pathophysiology and on emergent therapeutic initiatives"--Publisher's description.
Other form:Print version: Sigma proteins. Cham : Springer, [2017] 9783319658513
Standard no.:10.1007/978-3-319-65853-7

MARC

LEADER 00000cam a2200000Ii 4500
001 11384476
006 m o d
007 cr |||||||||||
008 171011t20172017sz a ob 000 0 eng d
005 20240509203449.6
015 |a GBB8J4809  |2 bnb 
016 7 |a 019091244  |2 Uk 
019 |a 1005967434  |a 1013509899  |a 1026998729  |a 1032269166  |a 1048148045  |a 1049849972  |a 1058454902  |a 1066629310  |a 1097096102 
020 |a 9783319658537  |q (electronic bk.) 
020 |a 3319658530  |q (electronic bk.) 
020 |z 9783319658513  |q (hardcover ;  |q alk. paper) 
020 |z 3319658514  |q (hardcover ;  |q alk. paper) 
024 7 |a 10.1007/978-3-319-65853-7  |2 doi 
035 |a (OCoLC)1005877842  |z (OCoLC)1005967434  |z (OCoLC)1013509899  |z (OCoLC)1026998729  |z (OCoLC)1032269166  |z (OCoLC)1048148045  |z (OCoLC)1049849972  |z (OCoLC)1058454902  |z (OCoLC)1066629310  |z (OCoLC)1097096102 
035 9 |a (OCLCCM-CC)1005877842 
037 |a com.springer.onix.9783319658537  |b Springer Nature 
040 |a YDX  |b eng  |e rda  |e pn  |c YDX  |d N$T  |d GW5XE  |d N$T  |d MMU  |d OCLCO  |d OCLCF  |d TFH  |d OCLCO  |d UAB  |d OCLCO  |d MERER  |d OCLCO  |d IOG  |d COO  |d AZU  |d UPM  |d VT2  |d OCLCO  |d JG0  |d SNK  |d U3W  |d CAUOI  |d OCLCQ  |d OCLCO  |d OCLCQ  |d KSU  |d CRU  |d OCLCQ  |d UCW  |d OCLCO  |d OCLCQ  |d OCLCO  |d AU@  |d OCLCQ  |d OCLCO  |d UKMGB  |d ESU  |d WYU  |d OCLCQ  |d OCLCO  |d LVT  |d OCLCQ  |d UKAHL  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCA 
049 |a MAIN 
050 4 |a RM301.41 
060 4 |a QU 55.7 
066 |c (3 
072 7 |a MED  |x 071000  |2 bisacsh 
072 7 |a PSAN  |2 bicssc 
245 0 0 |a Sigma proteins :  |b evolution of the concept of sigma receptors /  |c Felix J. Kim, Gavril W. Pasternak, editors. 
264 1 |a Cham, Switzerland :  |b Springer,  |c [2017] 
264 4 |c ©2017 
300 |a 1 online resource (viii, 330 pages) :  |b illustrations (chiefly color) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Handbook of experimental pharmacology,  |x 1865-0325 ;  |v volume 244 
504 |a Includes bibliographical references. 
505 0 |a Introduction to sigma proteins: evolution of the concept of sigma receptors / Felix J. Kim -- Structural insights into sigma1 function / Andrew Kruse -- 3d homology model of sigma1 receptor / Erik Laurini, Domenico Marson, Maurizio Fermeglia, Sabrina Pricl -- Medicinal chemistry of [sigma]1 receptor ligands: pharmacophore models, synthesis, structure affinity relationships, and pharmacological applications / Frauke Weber, Bernhard Wünsch -- Sigma-1 ([sigma]1) receptor in memory and neurodegenerative diseases / Tangui Maurice, Nino Goguadze -- Sigma-1 receptor and neuronal excitability / Saïd Kourrich -- Sigma-1 receptor and pain / Manuel Merlos, Luz Romero, Daniel Zamanillo, Carlos Plata-Salamán, José Miguel Vela -- Allosteric modulation of opioid g-protein coupled receptors by sigma1 receptors / Gavril W. Pasternak -- A role for sigma receptors in stimulant self-administration and addiction / Jonathan L. Katz, Takato Hiranita, Weimin C. Hong, Martin O. Job, Christopher R. McCurdy -- Sigma receptors and alcohol use disorders / Valentina Sabino, Pietro Cottone -- Sigma1 pharmacology in the context of cancer / Felix J. Kim, Christina M. Maher -- Molecular probes for imaging the sigma-2 receptor: in vitro and in vivo imaging studies / Chenbo Zeng, Elizabeth S. McDonald, Robert H. Mach. 
520 |6 880-01  |a "Two sigma receptor subtypes have been proposed, sigma1 and 2. Much of our understanding of this system is based on biochemical and pharmacological characterization of the cloned sigma1 receptor subtype (Sigma1). It has become clear that sigma receptors are not canonical receptors. Sigma1 is highly conserved among mammalian species, however, it does not share significant homology with any other mammalian protein. Although a range of structurally diverse small molecules bind Sigma1 with high affinity, and it has been associated with a broad range of signaling systems, Sigma1 itself has no known signaling or enzymatic activity. The evolution of this field over nearly four decades has more recently led to a fundamental shift in the concept of "sigma receptors" to what may more accurately and generally be called sigma proteins. Largely based on traditional pharmacologic approaches, the Sigma1 protein has been associated with a broad range of signaling systems, including G-protein coupled receptors, NMDA receptors, and ion channels. Sigma proteins have been linked to a range of physiological processes, including intracellular calcium signaling, neuroprotection, learning, memory, and cognition. Emerging genetic, clinical, and mechanism focused molecular pharmacology data demonstrate the involvement of proteins in a range of pathophysiologies and disorders including neurodegenerative disease, pain, addiction, psychomotor stimulant abuse, and cancer. However, an understanding of the physiological role of sigma proteins has remained elusive. Emerging data associate Sigma1 with chaperone-like activities or molecular scaffold functions. This book aims to provide an updated perspective on this rapidly evolving field undergoing changes in fundamental concepts of key importance to the discipline of pharmacology. It focusses on the reported roles of sigma proteins in pathophysiology and on emergent therapeutic initiatives"--Publisher's description. 
588 0 |a Online resource; title from electronic title page (SpringerLink, viewed November 2, 2017). 
650 0 |a Sigma receptors.  |0 http://id.loc.gov/authorities/subjects/sh2007000716 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 7 |a Sigma receptors.  |2 fast  |0 (OCoLC)fst01742279 
650 1 4 |a Biomedicine. 
650 2 4 |a Neurosciences. 
650 2 4 |a Human Physiology. 
650 2 4 |a Human Genetics. 
650 2 4 |a Cancer Research. 
650 2 4 |a Pharmaceutical Sciences/Technology. 
650 7 |a Physiology.  |2 bicssc 
650 7 |a Medical genetics.  |2 bicssc 
650 7 |a Oncology.  |2 bicssc 
650 7 |a Pharmaceutical technology.  |2 bicssc 
650 7 |a Neurosciences.  |2 bicssc 
650 1 2 |a Receptors, sigma. 
655 4 |a Electronic books. 
700 1 |a Kim, Felix J.,  |e editor. 
700 1 |a Pasternak, Gavril W.,  |e editor. 
776 0 8 |i Print version:  |t Sigma proteins.  |d Cham : Springer, [2017]  |z 9783319658513  |w (DLC) 2017944085  |w (OCoLC)1007835116 
830 0 |a Handbook of experimental pharmacology ;  |v v. 244.  |x 0171-2004  |0 http://id.loc.gov/authorities/names/n42012274 
880 |6 520-01/(3/r  |a "Two sigma receptor subtypes have been proposed, sigma1 and 2. Much of our understanding of this system is based on biochemical and pharmacological characterization of the cloned sigma1 receptor subtype (Sigma1). It has become clear that sigma receptors are not canonical receptors. Sigma1 is highly conserved among mammalian species, however, it does not share significant homology with any other mammalian protein. Although a range of structurally diverse small molecules bind Sigma1 with high affinity, and it has been associated with a broad range of signaling systems, Sigma1 itself has no known signaling or enzymatic activity. The evolution of this field over nearly four decades has more recently led to a fundamental shift in the concept of ٢sigma receptors٣ to what may more accurately and generally be called sigma proteins. Largely based on traditional pharmacologic approaches, the Sigma1 protein has been associated with a broad range of signaling systems, including G-protein coupled receptors, NMDA receptors, and ion channels. Sigma proteins have been linked to a range of physiological processes, including intracellular calcium signaling, neuroprotection, learning, memory, and cognition. Emerging genetic, clinical, and mechanism focused molecular pharmacology data demonstrate the involvement of proteins in a range of pathophysiologies and disorders including neurodegenerative disease, pain, addiction, psychomotor stimulant abuse, and cancer. However, an understanding of the physiological role of sigma proteins has remained elusive. Emerging data associate Sigma1 with chaperone-like activities or molecular scaffold functions. This book aims to provide an updated perspective on this rapidly evolving field undergoing changes in fundamental concepts of key importance to the discipline of pharmacology. It focusses on the reported roles of sigma proteins in pathophysiology and on emergent therapeutic initiatives"--Publisher's description. 
903 |a HeVa 
929 |a oclccm 
999 f f |i 6a2ed1c0-a57e-57e5-8bb0-ca230cb25387  |s c71c63be-cfc9-5c0f-b988-fd81d8021417 
928 |t Library of Congress classification  |a RM301.41  |l Online  |c UC-FullText  |u https://link.springer.com/10.1007/978-3-319-65853-7  |z Springer Nature  |g ebooks  |i 12549703